Literature DB >> 23659597

Significant morbidity and mortality attributable to rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation.

Rishikesh S Chavan1, Pia S Pannaraj, Ruth Ann Luna, Sara Szabo, Adekunle Adesina, James Versalovic, Robert A Krance, Alana A Kennedy-Nasser.   

Abstract

Rothia mucilaginosa is a gram-positive coccus that poses a diagnostic challenge and often requires DNA pyrosequencing for diagnosis as it can be easily mistaken for coagulase-negative staphylococci on initial culture results. While it is often times normal human oral and upper respiratory tract microbiota, it can be a virulent pathogen in immunocompromised patients. Most commonly, it causes bacteremia (catheter and non-catheter related) and meningitis in these patients. Our objective was to report the incidence of R. mucilaginosa infections in neutropenic children with hematological malignancies or following hematopoietic stem cell transplantation at a major children's hospital. We report 11 patients in this cohort who developed clinically significant R. mucilaginosa infections, including three deaths directly attributable to this microorganism. Three patients developed significant neurological involvement, accounting for two of the deaths, and one patient died of disseminated infection. Except for one, all patients had severe neutropenia, central line catheters, and mucosal breakdown at the time of infection. Patients who succumbed never achieved neutrophil recovery. In conclusion, R. mucilaginosa can lead to life-threatening infections in immunocompromised hosts, especially in profoundly neutropenic patients.

Entities:  

Mesh:

Year:  2013        PMID: 23659597     DOI: 10.3109/08880018.2013.783893

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  6 in total

1.  Rothia bacteremia: a 10-year experience at Mayo Clinic, Rochester, Minnesota.

Authors:  Poornima Ramanan; Jason N Barreto; Douglas R Osmon; Pritish K Tosh
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

Review 2.  Host-Microbiome Cross-talk in Oral Mucositis.

Authors:  R M Vasconcelos; N Sanfilippo; B J Paster; A R Kerr; Y Li; L Ramalho; E L Queiroz; B Smith; S T Sonis; P M Corby
Journal:  J Dent Res       Date:  2016-04-06       Impact factor: 6.116

3.  Characterization of the nasopharynx microbiota in patients with nasopharyngeal carcinoma vs. healthy controls.

Authors:  Longjie Li; Xiaoqin Deng; Yang Zou; XiuPeng Lv; Yanjie Guo
Journal:  Braz J Microbiol       Date:  2021-09-07       Impact factor: 2.214

4.  The treatment-naive microbiome in new-onset Crohn's disease.

Authors:  Subra Kugathasan; Lee A Denson; Dirk Gevers; Yoshiki Vázquez-Baeza; Will Van Treuren; Boyu Ren; Emma Schwager; Dan Knights; Se Jin Song; Moran Yassour; Xochitl C Morgan; Aleksandar D Kostic; Chengwei Luo; Antonio González; Daniel McDonald; Yael Haberman; Thomas Walters; Susan Baker; Joel Rosh; Michael Stephens; Melvin Heyman; James Markowitz; Robert Baldassano; Anne Griffiths; Francisco Sylvester; David Mack; Sandra Kim; Wallace Crandall; Jeffrey Hyams; Curtis Huttenhower; Rob Knight; Ramnik J Xavier
Journal:  Cell Host Microbe       Date:  2014-03-12       Impact factor: 21.023

5.  Meningitis in a patient with neutropenia due to Rothia mucilaginosa: a case report.

Authors:  Maxim Clauwaert; Patrick Druwé; Pieter Depuydt
Journal:  J Med Case Rep       Date:  2019-03-12

6.  Rothia mucilaginosa bacteremia, meningitis leading to diffuse cerebritis in an adolescent patient undergoing acute myeloid leukemia chemotherapy causing significant morbidity.

Authors:  Rachel Dena Robertson; Arun Panigrahi; Ritu Cheema
Journal:  SAGE Open Med Case Rep       Date:  2021-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.